Kết nối chức năng của thụ thể muscarinic acetylcholine M1 với Gαq/11 trong vỏ não trước trán bên trên ở bệnh nhân rối loạn tâm thần: một nghiên cứu sau tử vong

Caulfield MP, Birdsall NJM (1998) International union of pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 50:279–290 Eglen RM (2005) Muscarinic receptor subtype pharmacology and physiology. Prog Med Chem 43:105–136. https://doi.org/10.1016/S0079-6468(05)43004-0 Felder CC (1995) Muscarinic acetylcholine receptors: signal transduction through multiple effectors. FASEB J 9:619–625 Scarr E (2012) Muscarinic receptors: their roles in disorders of the central nervous system and potential as therapeutic targets. CNS Neurosci Ther 18:369–379. https://doi.org/10.1111/j.1755-5949.2011.00249.x Readler TJ, Bymaster FP, Tandon R, Copolov D, Dean B (2007) Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry 12:232–246. https://doi.org/10.1038/sj.mp.4001924 Bymaster FP, McKinzie DL, Felder CC, Wess J (2003) Use of M1–M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem Res 28:437–442 Jeon WJ, Dean B, Scarr E, Gibbons A (2015) The role of muscarinic receptors in the pathophysiology of mood disorders: a potential novel treatment? Curr Neuropharmacol 13:739–749 Scarr E (2009) Muscarinic receptors in psychiatric disorders––can we mimic 'health'? Neurosignals 17:298–310. https://doi.org/10.1159/000231896 Bennett JP Jr, Enna SJ, Bylund DB, Gillin JC, Wyatt RJ, Snyder SH (1979) Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry 36:927–934 Toru M, Watanabe S, Shibuya H, Nishikawa T, Noda K, Mitsushio H, Ichikawa H, Kunugi A, Takashima M, Mataga N, Ogawa A (1988) Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr Scand 78:121–137 Watanabe S, Nishikawa T, Takashima M, Toru M (1983) Increased muscarinic cholinergic receptors in prefrontal cortices of medicated schizophrenics. Life Sci 33:2187–2196 Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B (2000) Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 48:381–388 Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B (2001) Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann’s areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 158:918–925. https://doi.org/10.1176/appi.ajp.158.6.918 Dean B, Crook JM, Opeskin K, Hill C, Keks N, Copolov DL (1996) The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry 1:54–58 Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E (2002) Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 7:1083–1091 Deng C, Huang XF (2005) Decreased density of muscarinic receptors in the superior temporal gyrus in schizophrenia. J Neurosci Res 15:883–890. https://doi.org/10.1002/jnr.20600 Gibbons AS, Scarr E, McLean C, Sundram S, Dean B (2009) Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. J Affect Disord 116:184–191. https://doi.org/10.1016/j.jad.2008.11.015 Gibbons AS, Scarr E, Boer S, Money T, Jeon WJ, Felder C, Dean B (2013) Widespread decreases in cortical muscarinic receptors in a subset of people with schizophrenia. Int J Neuropsychopharmacol 16:37–46. https://doi.org/10.1017/S1461145712000028 Scarr E, Sundram S, Keriakous D, Dean B (2007) Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia. Biol Psychiatry 61:1161–1170. https://doi.org/10.1016/j.biopsych.2006.08.050 Scarr E, Cowie TF, Kanellakis S, Sundram S, Pantelis C, Dean B (2009) Decreased cortical muscarinic receptor define a subgroup of subjects with schizophrenia. Mol Psychiatry 14:1017–1023. https://doi.org/10.1038/mp.2008.28 Zavitsanou K, Katsifis A, Mattner F, Huang XF (2004) Investigation of M1/M4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 29:619–625. https://doi.org/10.1038/sj.npp.1300367 Crook JM, Dean B, Pavey G, Copolov D (1999) The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. Life Sci. 64:1761–1771 Gibbons AS, Jeon WJ, Scarr E, Dean B (2016) Changes in muscarinic M2 receptor levels in the cortex of subjects with bipolar disorder and major depressive disorder and in rats after treatment with mood stabilizers and antidepressants. Int J Neuropsychopharmacol 19:118. https://doi.org/10.1093/ijnp/pyv118 Zavitsanou K, Katsifis A, Yu Y, Huang XF (2005) M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. Brain Res Bull 65:397–403. https://doi.org/10.1016/j.brainresbull.2005.02.007 Jeon WJ, Gibbons AS, Dean B (2013) The use of a modified [3H]4-DAMP radioligand binding assay with increased selectivity for muscarinic M3 receptor shows that cortical CHRM3 levels are not altered in mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 47:7–12. https://doi.org/10.1016/j.pnpbp.2013.08.001 Salah-Uddin H, Scarr E, Pavey G, Harris K, Hagan JJ, Dean B, Challiss RA, Watson JM (2009) Altered M1 muscarinic acetylcholine receptor (CHRM1)-Gαq/11 coupling in a schizophrenia endophenotype. Neuropsychopharmacology 34:2156–2166. https://doi.org/10.1038/npp.2009.41 Salah-Uddin H, Thomas DR, Davies CH, Hagan JJ, Wood MD, Watson JM, Challiss RA (2008) Pharmacological assessment of M1 muscarinic acetylcholine receptor-Gq/11 protein coupling in membranes prepared from postmortem human brain tissue. J Pharmacol Exp Ther 325:869–874. https://doi.org/10.1124/jpet.108.137968 Odagaki Y, Kinoshita M, Ota T, Meana JJ, Callado LF, García-Sevilla JA (2017) Functional activation of Gαq coupled to 5-HT2A receptor and M1 muscarinic acetylcholine receptor in postmortem human cortical membranes. J Neural Transm 124:1123–1133. https://doi.org/10.1007/s00702-017-1749-0 Odagaki Y (2019) Guanosine-5′-O-(3-[35S]thio)triphosphate ([35S]GTPγS) binding/immunoprecipitation assay using magnetic beads coated with anti-Gα antibody in mammalian brain membranes. In: Odagaki Y, Borroto-Escuela DO (eds) Co-immunoprecipitation methods for brain tissue neuromethods, vol 144. Springer Nature, New York, pp 97–108 Odagaki Y, Kinoshita M, Ota T, Meana JJ, Callado LF, García-Sevilla JA (2015) Adenosine A1 receptors are selectively coupled to Gαi-3 in postmortem human brain cortex: guanosine-5′-O-(3-[35S]thio)triphosphate ([35S]GTPγS) binding/immunoprecipitation study. Eur J Pharmacol 764:592–598. https://doi.org/10.1016/j.ejphar.2015.07.049 Odagaki Y, Kinoshita M, Ota T, Meana JJ, Callado LF, García-Sevilla JA (2019) Optimization and pharmacological characterization of receptor-mediated Gi/o activation in postmortem human prefrontal cortex. Basic Clin Pharmacol Toxicol 124:649–659. https://doi.org/10.1111/bcpt.13183 Bowie CR, Harvey PD (2006) Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr Dis Treat 2:531–536 Tripathi A, Kar SK, Shukla R (2018) Cognitive deficits in schizophrenia: understanding the biological correlates and remediation strategies. Clin Psychopharmacol Neurosci 16:7–17. https://doi.org/10.9758/cpn.2018.16.1.7 MacQueen GM, Memedovich KA (2017) Cognitive dysfunction in major depression and bipolar disorder: assessment and treatment options. Psychiatry Clin Neurosci 71:18–27. https://doi.org/10.1111/pcn.12463 Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR (1991) Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci 11:3218–3226 Levey AI, Edmunds SM, Heilman CJ, Desmond TJ, Frey KA (1994) Localization of muscarinic m3 receptor protein and M3 receptor binding in rat brain. Neuroscience 63:207–221 Mysliveček J, Kvetňanský R (2006) The effects of stress on muscarinic receptors. Heterologous receptor regulation: yes or no? Auton Autacoid Pharmacol 26:235–251 van Koppen CJ, Kaiser B (2003) Regulation of muscarinic acetylcholine receptor signaling. Pharmacol Ther 98:197–220 Quitterer U, Lohse MJ (1999) Crosstalk between Gαi- and Gαq-coupled receptors is mediated by Gβγ exchange. Proc Natl Acad Sci USA 96:10626–10631 Cannon DM, Carson RE, Nugent AC, Eckelman WC, Kiesewetter DO, Williams J, Rollis D, Drevets M, Gandhi S, Solorio G, Drevets WC (2006) Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch Gen Psychiatry 63:741–747 Friedman E, Wang HY (1996) Receptor-mediated activation of G proteins is increased in postmortem brains of bipolar affective disorder subjects. J Neurochem 67:1145–1152 Avissar S, Schreiber G, Danon A, Belmaker RH (1988) Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex. Nature 331:440–442 Avissar S, Schreiber G (1992) Ziskind-Somerfeld research Award. The involvement of guanine nucleotide binding proteins in the pathogenesis and treatment of affective disorders. Biol Psychiatry 31:435–459 Avissar S, Schreiber G (2002) Toward molecular diagnostics of mood disorders in psychiatry. Trends Mol Med 8:294–300 Schreiber G, Avissar S (1991) Lithium sensitive G protein hyperfunction: a dynamic model for the pathogenesis of bipolar affective disorder. Med Hypotheses 35:237–243 Odagaki Y (2005) Transmembrane signal transduction via G proteins implicated in affective disorders. In: Brown MR (ed) Focus on bipolar disorder research. Nova Science Publishers, New York, pp 75–112 González-Maeso J, Meana JJ (2006) Heterotrimeric G proteins: insights into the neurobiology of mood disorders. Curr Neuropharmacol 4:127–138 Odagaki Y, Nishi N, Koyama T (1997) Lack of interfering effects of lithium on receptor/G protein coupling in human platelet and rat brain membranes. Biol Psychiatry 42:697–703